Cargando…

Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status

BACKGROUND: While reduction of accumulated body fluid using loop diuretics is a commonly used therapeutic option for acute heart failure (AHF), some patients, especially those with chronic kidney disease (CKD), show significantly poor treatment response to loop diuretics. Tolvaptan (TLV) has shown e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Tomohiko, Miura, Shin-ichiro, Shirai, Kazuyuki, Urata, Hidenori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306139/ https://www.ncbi.nlm.nih.gov/pubmed/30627278 http://dx.doi.org/10.14740/jocmr3671

Ejemplares similares

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
por: Ikeda, Shuntaro, et al.
Publicado: (2017)

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure
por: Kin, Hiromi, et al.
Publicado: (2020)

Tolvaptan: A Novel Diuretic in Heart Failure Management
por: Zulkifli Amin, Hilman, et al.
Publicado: (2016)

Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project
por: Pose, Antonio, et al.
Publicado: (2017)

Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study
por: Nishino, Masami, et al.
Publicado: (2022)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice
por: Mullens, Wilfried, et al.
Publicado: (2023)

Tolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale
por: Minh, Nhat Giang, et al.
Publicado: (2022)

Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction
por: Matsue, Yuya, et al.
Publicado: (2017)

Two Years Efficacy of Paclitaxel-Coated Balloon Dilation for In-Stent Renal Artery Restenosis Due to Takayasu Arteritis
por: Yamamoto, Tomohiko, et al.
Publicado: (2019)

Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020)

Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure
por: Yoshioka, Kenji, et al.
Publicado: (2022)

Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial
por: Palazzuoli, Alberto, et al.
Publicado: (2014)

Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
por: Okada, Tomoaki, et al.
Publicado: (2023)

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)
por: Ng, Tien M.H., et al.
Publicado: (2020)

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan
por: Kramers, Bart J., et al.
Publicado: (2018)

Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure
por: Niikura, Hiroki, et al.
Publicado: (2017)

Tolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration
por: Ndrepepa, Gjin
Publicado: (2017)

Effect of diuretic infusion clinic in preventing hospitalization for patients with decompensating heart failure
por: Alghalayini, Kamal Waheeb
Publicado: (2020)

Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis
por: Brisco‐Bacik, Meredith A., et al.
Publicado: (2018)

Association between changes in loop diuretic dose and outcomes in acute heart failure
por: Seko, Yuta, et al.
Publicado: (2023)

High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients
por: Ferreira, João Pedro, et al.
Publicado: (2014)

Triple Diuretics and Aquaretic Strategy for Acute Decompensated Heart Failure due to Volume Overload
por: Jermyn, Rita, et al.
Publicado: (2013)

Trial of Oral Diuretics Prior to Discharge Is Not Associated With Improved Outcomes in Decompensated Heart Failure
por: Mohammad, Adeba, et al.
Publicado: (2021)

A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan
por: Takimura, Hideyuki, et al.
Publicado: (2018)

Toward quantification of loop diuretic responsiveness for congestive heart failure
por: Oyama, Mark A., et al.
Publicado: (2022)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
por: Nakagaito, Masaki, et al.
Publicado: (2021)

Successful Depressor Effect Concomitant with Complete Normalization of High Renin and Aldosterone Profile by Percutaneous Transluminal Renal Angioplasty in a Patient with Acute Exacerbated Heart Failure with Preserved Ejection Fraction
por: Takamiya, Yosuke, et al.
Publicado: (2019)

Loop Diuretic Administration in Patients with Acute Heart Failure and Reduced Systolic Function: Effects of Different Intravenous Diuretic Doses and Diuretic Response Measurements
por: Ruocco, Gaetano, et al.
Publicado: (2019)

Loop Diuretics in Clinical Practice
por: Oh, Se Won, et al.
Publicado: (2015)

Novel Intranasal Loop Diuretic
por: Esque, Benjamin, et al.
Publicado: (2023)

Point-of-Care, Ultraportable Echocardiography Predicts Diuretic Response in Patients Admitted with Acute Decompensated Heart Failure
por: Krishnan, Dena K., et al.
Publicado: (2016)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney
por: Palazzuoli, Alberto, et al.
Publicado: (2015)

Use of loop diuretics in patients with chronic heart failure: an observational overview
por: Scholte, Niels TB, et al.
Publicado: (2023)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Six-Month Predictive Value of Diuretic Resistance Formulas in Discharged Heart Failure Patients after an Acute Decompensation
por: Feola, Mauro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j2hptrjhmjgonnj9rtgkdjlc1c